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tient visit for 12 months. Annual average visit days of outpatients were 37. Annual
overall costs per patient were 13.4million Koreanwon (KRW), of which 10.5million
KRW (78.6%)was drug costs because of costly TNF antagonist. Inspection cost came
next with 5.6% of the total costs, followed by hospitalization cost (4.6%), operation
cost (4.0%), and doctor’s fee (3.2%).Mean out-of–pocket expenditurewas 3.7million
KRW, 27.1% of the overall costs. As age increased, so did the total costs. Male,
medical aid, and patients with hospitalization or surgery were associated with
significantly higher costs than female, health insurance, and inexperienced pa-
tients of hospitalization or surgery respectively(p0.05). CONCLUSIONS: Direct
medical costs per capita of RA patients receiving TNF antagonist in Koreawere 13.4
million KRW. The economic burden of RA patients is strongly influenced by TNF
antagonist.
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OBJECTIVES: To describe the association between serum uric acid (sUA) levels and
gout-related healthcare utilization and costs. METHODS: A retrospective analysis
was conducted using a database from a regional managed care organization. Pa-
tients with primary gout were included in the study if they met the following
criteria between 2006 and 2007: (1) age 18; (2) 1 diagnosis of gout (ICD-9-CM
274.xx), or 1 prescription gout-related medications (colchicine, allopurinol, pro-
benecid); (3) 12 months continuous eligibility pre- and post- either the first gout
diagnosis or first pharmacy claim date (index date). Patients with cancer diagnoses
were excluded. Patients were classified into three sUA levels based on the mea-
surement taken on the date closest to the index date: 6.0 mg/dL, 6.0- 8.99 mg/dL,
and 9.0 mg/dL. Healthcare costs in the12 months post index period were com-
pared across the three sUA levels using Kruskal-Wallis tests. RESULTS: A total of
1,622 patients were identified; 374 (23.0%) had an sUA 6.0 mg/dL, 788 (48.0%) had
an sUA of 6.0-8.99 mg/dL, and 470 (29.0%) had an sUA 9.0 mg/dL. The mean
gout-related healthcare costs were $217(standard deviation [SD] $631), $426 (SD
$4330), and $647(SD $4274) for patients with sUA 6.0 mg/dL, 6.0- 8.99 mg/dL, and
9.0 mg/dL, respectively (p0.0001). Statistically significant differences were also
detected in the gout-related outpatient costs, gout-related emergency department
costs, and gout-related prescription costs among the three groups. CONCLUSIONS:
Our results showed that there is a positive association between sUA levels and
gout-related healthcare utilization and costs. Lowering andmaintaining sUA levels
6 mg/dL may lead to lower gout-related healthcare costs and decrease gout-
related utilization of services. Further study is warranted.
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OBJECTIVES: Oral bisphosphonate therapy reduces the risk of fractures and asso-
ciated morbidity in women with post-menopausal osteoporosis. This study evalu-
ated how failure to persist and comply with oral bisphosphonates impacts on the
use of health care services and costs. METHODS: Retrospective cohort analysis of
6,870 womenwith incident bisphosphonate prescribing in UK primary care. Persis-
tence was defined as no gaps in refill of30 days; compliance wasmeasured using
medication possession ratio (MPR 80). The impact of non-persistence and non-
compliance on the intensity of health service use (HSU) in the 24-month period
following treatment was analyzed using negative binomial regression; the impact
on costs was analysed using gamma regression. Primary care data, linked Hospital
Episode Statistic data andnationally available prescribing andhealth care cost data
were used. RESULTS: Persistence and compliance in the 24-month period was
32.4% and 59.2% respectively. In multivariable analysis, non-persistent patients
had a 15% increased frequency of primary care contact (incident rate ratio (IRR):
1.15; 95% CI: 1.12-1.19) and a 92% increased (IRR: 1.92; 95% CI: 1.74-2.12) frequency
of inpatient hospitalisation for any cause. The IRR of osteoporosis-related hospi-
talisations for non-persistent patients was 2.23 (95% CI: 1.66-2.98). Non-compliant
patients had a 5% increased frequency of primary care contact (IRR: 1.05; 95% CI:
1.02-1.18), a 55% increased (IRR:1.55; 95% CI: 1.41-1.69) frequency of all-cause inpa-
tient hospitalisation and a 37% increased frequency of osteoporosis-related hospi-
talisations (IRR: 1.37; 95% CI: 1.07 1.75). Average total health care cost was signif-
icantly higher among non-persistent (£3,557 [95% CI: £3,372-£3,742]) than
persistent patients (£2,540 [95% CI: £2,370- £2,710]). Among non-compliant pa-
tients, average total health care costs was £3,592 (95% CI: £3,369 –3,816) compared
to compliant patients- £3,028 (95% CI: £2,853- £3,202)- a cost difference of £564.
CONCLUSIONS: Suboptimal persistence and compliance with oral bisphospho-
nates is associated with significant increases in HSU and costs.
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OBJECTIVES: To estimate the differences in fracture-related treatment costs (FTC)
between osteoporosis patients with and without proton pump inhibitor (PPI) use.
METHODS: Data from the 2001-2008 Medical Expenditure Panel Surveys was used
to identify osteoporosis patients50 years old through an ICD-9-CM code of 733 or
clinical classification code of 206. Patients were categorized into two groups based
on PPI use. Considered medications included osteoporosis agents (bisphospho-
nates, hormone therapy, and raloxifene) and corticosteroids (excluding topicals).
Fractures were identified based on ICD-9-CM codes 804-829. Mean of treatment
costs were calculated with bootstrap confidence interval due to skewed costs. FTC
were estimated using generalized linear model with log link function and gamma
distribution. First, FTC for patients treated with PPI were predicted using the esti-
mated coefficients from patients without PPIs using a generalized linear model
with adjustments for patient characteristics, medication use, and comorbidities.
Second, attributable costs to the use of PPI were estimated by the difference be-
tween predicted and observed costs for PPI users. Treatment costs for one year
were calculated and converted to 2009 U.S. dollar using appropriate price indices.
RESULTS:We identified 4,979 patients with osteoporosis. PPI use was found in 970
patients and in 4,009 it was not. Unadjusted cost differences showed patients with
PPI use had similar osteoporosis-related costs (excluding fracture costs) to patients
without ($883 vs. $798). However, patients treated with PPI had higher FTC by $335
thanpatientswithout PPI use ($709 vs. $374). After adjusting for the study variables,
PPI use was associated with an increase in FTC by 63% when compared to patients
not taking PPIs. CONCLUSIONS: Use of PPIs increases the economic burden of
osteoporosis patients primarily due to fracture-related costs. Additional studies
are warranted to further explore the cost attributable to fracture due to use of PPIs
in osteoporosis patients.
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OBJECTIVES: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune inflamma-
tory disease in childhood affecting about 1 in 1000 children. The objectives of this
study were to analyze drug utilization in JIA, particularly the use of anti-TNFs and
to estimate health care resources utilization associated with JIA management.
METHODS: A retrospective prescription claims analysis of a random sample of
patients from the Régie de l’assurance maladie du Québec (RAMQ) provincial
health plan (Québec, Canada) database was conducted. Data of patients with a
diagnosis of rheumatoid arthritis and aged less than 20 years were obtained for the
period from January 1998 to December 2009. Healthcare resources consumed by
patients with JIA were identified in terms of visits to physicians, physician’s inter-
ventions, arthritis related medications, other medications, emergency visits and
hospitalizations. RESULTS: Data were obtained from the RAMQ for a total of 995
patientswith amean age of 11.4 years (SD5.2). Anti-TNFswere used by 32 patients
(3.2%). In the year following initiation of anti-TNF treatment, reductions in all
healthcare resources used were observed, the greatest decreases being for the
average number of medical visits per patient (before/after: 14.7 vs. 8.1) and average
number of physician’s interventions per patient (before/after: 5.8 vs. 3.3). Decreases
in costs of all healthcare resources were also seen and costs associated with hos-
pitalization decrease significantly by an average of CAN$1,356 per patient (p0.05)
in the year following the initiation of anti-TNF treatment. CONCLUSIONS: Anti-
TNFs have demonstrated significant clinical benefits and on other aspects of JIA
patients’ lives, such as functionality, school performance, or health-related quality
of life. Results of these claims analyses showed that the use of anti-TNFs was
associated with decreases in healthcare utilization in the year following initiation
of treatment which translated in reductions in the cost of healthcare resources for
JIA patients.
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OBJECTIVES: To determine the costeffectiveness of abatacept or infliximab in
patients with rheumatoid arthritis (RA) with inadequate response tomethotrexate
(IRMTX) in Venezuela. METHODS: Adapting a previously validated model, dy-
namic simulation techniques and clinical data frompublished literaturewere used
to compare the clinical events, quality of life, and direct medical costs of abatacept
and infliximab to MTX. The prevalence of the disease and the demographic char-
acteristics for Venezuela, were used to assign a pretreatment score relative to the
Health Assessment Questionnaire (HAQ). Then, HAQ scores were projected over
time according to the efficacy of each treatment. The costs associated with each
treatment and the disease were calculated from private and public hospitals, for a
reference patient weighting 60 kg, and validated with a group of experts. The re-
sults of the model were analyzed over a 10year time horizon using the payer’s
perspective, and a3% annual discount. Univariate and probabilistic sensitivity
analyses for relevant parameters were performed to assess the robustness of the
results of themodel. RESULTS:A hypothetical cohort of 1,000 patients with RA and
IR MTX in Venezuela,followed for 10 years, resulted in mean treatment costs of:
U$5,126, U$57,824, andU$27,842 dollars, forMTX, abatacept, and infliximab,respec-
tively. Total direct medical costs(discounted) per patient were U$ 50,441 (48,819
A126 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
